Minnetonka-based Osprey Medical has raised about $26 million to bolster its U.S. sales force and ramp up efforts to sell medical devices that reduce the amount of chemical agents used during millions of live-motion X-rays to treat vascular problems.
Earlier this year, the U.S. Food and Drug Administration cleared a new product from Osprey called the DyeTect automated contrast monitoring system, which increased Osprey’s potential global market to $1.8 billion, according to a recent presentation from the company.
